BioAmber Inc. (NYSE:BIOA) Director George Frederick John Gosbee acquired 25,000 shares of the company’s stock in a transaction dated Wednesday, November 9th. The stock was acquired at an average cost of $3.87 per share, with a total value of $96,750.00. Following the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at $96,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

BioAmber Inc. (NYSE:BIOA) opened at 5.15 on Wednesday. The stock’s market capitalization is $148.38 million. The stock has a 50 day moving average of $4.41 and a 200 day moving average of $3.78. BioAmber Inc. has a 52 week low of $2.86 and a 52 week high of $8.73.

Insider Buying and Selling by Quarter for BioAmber (NYSE:BIOA)

Several research firms have recently issued reports on BIOA. Zacks Investment Research raised shares of BioAmber from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research report on Tuesday, November 8th. Canaccord Genuity reissued a “buy” rating and issued a $5.50 price objective on shares of BioAmber in a research report on Sunday, August 7th. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $12.55.

Several hedge funds have recently bought and sold shares of BIOA. Wells Fargo & Company MN boosted its stake in BioAmber by 47.6% in the third quarter. Wells Fargo & Company MN now owns 58,393 shares of the company’s stock valued at $247,000 after buying an additional 18,844 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in BioAmber by 21.0% in the third quarter. Essex Investment Management Co. LLC now owns 122,619 shares of the company’s stock valued at $520,000 after buying an additional 21,257 shares in the last quarter. Finally, Robecosam AG bought a new stake in BioAmber during the first quarter valued at approximately $1,688,000. Institutional investors and hedge funds own 42.24% of the company’s stock.

BioAmber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

5 Day Chart for NYSE:BIOA

Receive News & Stock Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related stocks with our FREE daily email newsletter.